Nicholas McAndrew, MD, MSCE, shares his perspectives on the updated overall survival results from the phase 3 MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer treated with fulvestrant plus or minus ribociclib.
Back
Post-Conference Perspectives: Hormone Receptor-Positive Advanced Breast Cancer
Nicholas McAndrew, MD, MSCE provides his perspective on how findings reported at ASCO 2021 will impact treatment of patients with PIK3CA-mutated HR+, HER2- advanced breast cancer. In this series, Dr. McAndrew reviews the overall survival results from MONALEESA-3, the joint analysis of SOLAR-1 and X2101, the design and outcomes of the BYLieve trial, and real-world clinical outcomes using alpelisib in patients with PIK3CA-mutated HR+, HER2- advanced breast cancer.
Post-Conference Perspectives: Hormone Receptor-Positive Advanced Breast Cancer
Episodes
All
All
Nicholas McAndrew, MD, MSCE, reviews PIK3CA mutations in HR+/HER2- breast cancer and provides his perspective on the joint analysis of SOLAR-1 and CBYL719X2101 in which patients were given alpelisib and fulvestrant.
Nicholas McAndrew, MD, MSCE, discusses the impact of CDK4/6 therapy duration on alpelisib benefit in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer from the BYLieve trial.
Nicholas McAndrew, MD, MSCE, provides his perspective on real-world clinical outcomes using alpelisib in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.
Nicholas McAndrew, MD, MSCE, provides final thoughts on findings reported at ASCO 2021 for patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
3
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
4
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC
5